Retinal Vein Occlusion Treatment Disease Market Size Worth USD 5.28 Billion by 2035, Expanding at a 6.44% CAGR – SNS Insider
Austin, United States, June 15, 2026 (GLOBE NEWSWIRE) -- “According to SNS Insider, the Retinal Vein Occlusion Treatment Disease Market was valued at USD 2.82 billion in 2025 and is projected to reach USD 5.28 billion by 2035, expanding at a CAGR of 6.44% during 2026–2035.”
The global retinal vein occlusion (RVO) treatment market is witnessing steady growth, supported by the increased incidence of RVO owing to the systemic risk factors such as hypertension, diabetes, hyperlipidemia, and glaucoma among the aging demographic worldwide, as well as the increasing usage of intravitreal anti-VEGF treatment, which has proven better outcomes compared to other modalities like lasers and corticosteroids.
Get a Sample Report of Retinal Vein Occlusion Treatment Disease Market Forecast @ https://www.snsinsider.com/sample-request/5875
Aging Population Increasing RVO Incidence to Augment Market Growth Globally
The structural certainty of aging demographics represents the most predictable driver of growth for the RVO treatment market. With its robust correlation to aging and a marked rise in incidence after 60, causing disproportionately high RVO prevalence among the fastest-growing demographic group worldwide, the RVO treatment market is poised for sustained growth due to the compounding nature of demographic shifts annually. The World Health Organization (WHO) estimate of doubling the current figure from 1 billion individuals aged 65+ globally in 2020 to reach 2 billion by 2050 provides the commercial demand curve.
Leading Market Players Listed in the Retinal Vein Occlusion Treatment Disease Market Report are:
Segmentation Analysis:
By Type
Central Retinal Vein Occlusion (CRVO) segment dominated the market with approximately 58% share in 2025 due to its more severe clinical course whose higher rate of ischemic progression, more frequent neovascular complications, and greater macular oedema severity globally. Branch Retinal Vein Occlusion (BRVO) segment is the fastest growing segment due to its increasing prevalence globally.
By Treatment
Anti-VEGF agents segment dominated the market with approximately 65% share in 2025 due to the compelling evidence base demonstrating superior visual acuity outcomes relative to observation, laser photocoagulation, and corticosteroid alternatives globally. Corticosteroid medications are the fastest-growing segment owing to the dexamethasone intravitreal implant’s distinct mechanism globally.
By Route of Administration
The intravitreal injection segment dominated the Retinal Vein Occlusion Treatment Market with approximately 82% market share in 2025 owing to its ability to deliver anti-VEGF agents and corticosteroids directly to the retina. The oral/systemic segment continues to maintain commercial relevance due to its role in managing underlying cardiovascular and metabolic risk factors globally.
By End User
The hospitals & clinics segment dominated the market with approximately 52% share in 2025 as intravitreal injection procedure’s clinical environment requirement creates inherent procurement concentration in specialist ophthalmological outpatient facilities whose sterile injection suite. Retail pharmacy is the fastest-growing end user due to the oral and topical adjunctive medication market’s expansion globally.
Regional Insights:
The North America segment led the worldwide revenue generation by the treatment of RVO during 2025 due to its status as the area with maximum spending on healthcare. The U.S., which makes up 87.4% of North American revenues, uses such products as Eylea from Regeneron Pharmaceuticals, Lucentis, and Vabysmo from Genentech, as well as Ozurdex from AbbVie.
The Europe Retinal Vein Occlusion Treatment Disease Market is estimated to be USD 0.82 Billion in 2025 and is projected to reach USD 1.49 Billion by 2035, growing at a CAGR of 6.15% during 2026–2035. The European market for RVO treatments is technologically mature with the approval indications of the EMA’s drug, the anti-VEGF provision in national reimbursement schemes, and advanced training in ophthalmology contributing to organized procurement.
The Asia Pacific region has the highest growth rate for the RVO treatment market on account of the rapid increase in the geriatric population in China, Japan, South Korea, and India wherein the occurrence of RVO increases with age. Other factors responsible for this include the rise in hypertension and diabetes cases.
Purchase Single User PDF of Retinal Vein Occlusion Treatment Disease Market Report @ https://www.snsinsider.com/checkout/5875
Recent Developments:
Exclusive Sections of the Report (The USPs):
Retinal Vein Occlusion Treatment Disease Market Report Scope
Related Market Reports
Retinal Biologics Market Size & Growth 2026
Retinal Surgery Market Share & Trends 2026
Diabetic Retinopathy Market Growth & Outlook 2026
Dry Age-Related Macular Degeneration Market Size & Trends 2026
Glaucoma Therapeutics Market Share & Analysis 2026
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.